Paroxetine Mesylate Targets MET/ERBB3 in Colorectal Cancer Models

Study Background and Research Question

Colorectal cancer (CRC) remains a major global health challenge, ranking as the third most common malignancy and a leading cause of cancer-related mortality. With approximately 30% of CRC patients presenting with metastasis at diagnosis, the search for more effective therapeutic strategies is urgent. Conventional treatments, including 5-fluorouracil and targeted antibodies such as cetuximab, have limited long-term efficacy and are often associated with resistance and high costs. Against this backdrop, the concept of drug repositioning—repurposing clinically approved drugs for novel indications—has gained traction in oncology. Recent studies have suggested that selective serotonin reuptake inhibitors (SSRIs), typically prescribed for psychiatric disorders, may possess anticancer properties, but the underlying mechanisms have remained unclear. The reference study (Jang et al., 2019) specifically investigated whether Paroxetine Mesylate, a well-characterized SSRI, could be repurposed as a therapeutic agent against human colon cancer and elucidated its molecular targets in this context.

Key Innovation from the Reference Study

The central innovation of this study lies in identifying Paroxetine Mesylate as a dual inhibitor of the receptor tyrosine kinases MET and ERBB3 in colorectal cancer models. By leveraging an existing psychiatric medication with a favorable clinical safety profile, the authors demonstrated a new application for Paroxetine Mesylate in oncology, specifically through molecular inhibition of pathways implicated in tumor proliferation and survival. This work advances the drug repositioning paradigm by providing robust mechanistic evidence for the anticancer effects of a selective serotonin reuptake inhibitor, and it highlights the therapeutic relevance of targeting MET and ERBB3 in CRC.

Methods and Experimental Design Insights

The study employed a combination of in vitro and in vivo approaches. Two human CRC cell lines, HCT116 and HT29, were used to assess the cytotoxic and anti-proliferative effects of Paroxetine Mesylate. Key experimental assays included:

• Cell viability assays to quantify the effects of Paroxetine on cancer cell survival.
• Apoptosis detection by flow cytometry and caspase-3 activation.
• Colony formation and 3D spheroid assays to evaluate long-term proliferative capacity and tumorigenic potential.
• Western blot analysis to probe the phosphorylation status and activity of MET, ERBB3, and downstream kinases including AKT, ERK, p38, and JNK.
• In vivo xenograft experiments in athymic nude mice implanted with HT29 cells to assess tumor growth inhibition.

This rigorous multi-layered approach allowed the investigators to map both the phenotypic consequences and molecular underpinnings of Paroxetine Mesylate treatment in CRC models.

Core Findings and Why They Matter

Paroxetine Mesylate treatment led to a pronounced reduction in cell viability in both HCT116 and HT29 CRC cell lines, accompanied by a significant increase in apoptosis. The compound robustly inhibited the formation of both colonies and 3D spheroids—key indicators of tumorigenic capacity. Mechanistically, these effects were linked to inhibition of MET and ERBB3 phosphorylation and subsequent downregulation of the AKT, ERK, and p38 signaling pathways, while activating JNK and caspase-3 to induce apoptosis (Jang et al., 2019).

In vivo, Paroxetine Mesylate markedly suppressed tumor growth in HT29 xenografts, providing translational support for its potential anticancer efficacy. These findings are particularly significant because MET and ERBB3 are established drivers of CRC growth, metastasis, and resistance to conventional therapies. By inhibiting these receptor tyrosine kinases, Paroxetine Mesylate acts as a multi-kinase modulator—an approach that may circumvent some forms of acquired resistance observed with single-target agents.

Comparison with Existing Internal Articles

Recent internal resources have begun to address the intersection of psychiatric and oncology research with Paroxetine Mesylate. For instance, the article "Paroxetine Mesylate: Applied Research Workflows in Oncology & Beyond" outlines detailed protocols for deploying Paroxetine Mesylate in advanced cancer models, emphasizing its dual function as a selective serotonin reuptake inhibitor and a multi-kinase agent. Similarly, "Paroxetine Mesylate: Advanced SSRI Applications in Oncology Research" highlights the molecule's ability to inhibit both MET and ERBB3, aligning with the mechanistic insights from the reference study. These internal articles corroborate the workflow enhancements and experimental protocols necessary for maximizing the translational potential of Paroxetine Mesylate in oncology settings.

Moreover, the broader kinase inhibition profile, including cytochrome P450 inhibitor CYP2D6, G protein-coupled receptor kinase 2 inhibitor (GRK2), and KIT kinase inhibitor activity, is discussed in product-focused resources and extends the utility of Paroxetine Mesylate for researchers interested in polypharmacological interventions, as reported in the product information.

Limitations and Transferability

While the findings are robust, several limitations should be considered. The study's preclinical nature means that in vitro and xenograft results may not fully predict clinical efficacy in humans. The anticancer activity was demonstrated in only two CRC cell lines; broader validation across genetically diverse models is needed. The in vivo experiments, while compelling, were performed in immunocompromised mice, which do not recapitulate the complexity of human tumor-immune interactions. Furthermore, while Paroxetine Mesylate's inhibition of MET and ERBB3 is clear, its additional targets—such as CYP2D6 or GRK2—may produce off-target effects that require further pharmacodynamic and safety evaluation in oncology contexts.

Translating these findings to the clinic will necessitate careful dose optimization, pharmacokinetic studies, and assessment of potential drug-drug interactions, especially considering Paroxetine Mesylate's established profile as a cytochrome P450 inhibitor. Nonetheless, these limitations are inherent to the early stages of drug repurposing research and provide a roadmap for subsequent investigation.

Protocol Parameters

• Cell line selection: HCT116 and HT29 human colon cancer cells are recommended for initial in vitro assays when evaluating MET/ERBB3 inhibition.
• Compound concentration: Literature reports effective concentrations for apoptosis and proliferation assays ranging from 7 to 26 μM, with dose-response curves recommended for each cell line (reference study).
• Apoptosis detection: Use caspase-3 activation and flow cytometry-based Annexin V/PI staining after 24–48 hours of treatment for robust quantification of apoptotic fractions.
• Spheroid assay setup: Employ 3D spheroid culture conditions to assess inhibition of tumorigenic potential over 7–10 days; monitor spheroid size and integrity as primary endpoints.
• In vivo modeling: For xenograft studies, inject HT29 cells subcutaneously into athymic nude mice and administer Paroxetine Mesylate intraperitoneally at literature-backed dosages; monitor tumor volume and animal weight as indicators of efficacy and toxicity.
• Western blot analysis: Include antibodies against phospho-MET, phospho-ERBB3, AKT, ERK, p38, and JNK to map pathway modulation.
• Control agents: Incorporate established MET or ERBB3 inhibitors as positive controls to benchmark Paroxetine Mesylate's efficacy.

Why this cross-domain matters, maturity, and limitations

The repositioning of Paroxetine Mesylate—a molecule long used as a psychiatric agent—as an anticancer agent illustrates the growing maturity of polypharmacological strategies in drug discovery. The demonstration that a selective serotonin reuptake inhibitor can act as a receptor tyrosine kinase MET inhibitor and ERBB3 kinase inhibitor in colorectal cancer models highlights the fundamental interconnectedness of neuropharmacology and oncology. However, while preclinical data are promising, translation to clinical oncology will require robust safety and efficacy data in diverse patient populations and careful consideration of drug-drug interactions given Paroxetine's cytochrome P450 inhibitory profile. These caveats underscore the importance of multi-disciplinary collaboration in advancing cross-domain therapeutics.

Research Support Resources

Researchers interested in further exploring the anticancer and multi-kinase properties of selective serotonin reuptake inhibitors can leverage Paroxetine Mesylate (SKU C8698) in their experimental workflows. This compound, available from APExBIO, offers a well-documented profile as both a SERT inhibitor and a MET/ERBB3 modulator, and has been utilized across in vitro and in vivo oncology models. For detailed protocol recommendations and troubleshooting, internal resources such as "Optimizing Oncology Protocols with SSRI Precision" provide further guidance on experimental design and translational considerations.